Corbus Pharmaceuticals Holdings, Inc. financial data

Symbol
CRBP on Nasdaq
Industry
Pharmaceutical Preparations
Location
500 River Ridge Drive, Norwood, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
SAV Acquisition Corp (to 1/10/2014)
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 796 % +440%
Debt-to-equity 16 % -97.8%
Return On Equity -31.2 % +96.6%
Return On Assets -26.9 % +75.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.2M shares +16.6%
Common Stock, Shares, Outstanding 12.2M shares +175%
Entity Public Float 428M USD +1138%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 10.9M shares +152%
Weighted Average Number of Shares Outstanding, Diluted 10.9M shares +152%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 32.2M USD +3.38%
General and Administrative Expense 16.5M USD +18.6%
Operating Income (Loss) -48.7M USD -8.08%
Nonoperating Income (Expense) 8.51M USD +1696%
Net Income (Loss) Attributable to Parent -40.2M USD +9.85%
Earnings Per Share, Basic -3.68 USD/shares +64.3%
Earnings Per Share, Diluted -3.68 USD/shares +64.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.2M USD +25.3%
Assets, Current 153M USD +550%
Property, Plant and Equipment, Net 385K USD -60.4%
Operating Lease, Right-of-Use Asset 2.13M USD -30.4%
Other Assets, Noncurrent 0 USD -100%
Assets 156M USD +451%
Accounts Payable, Current 4.79M USD +50.6%
Employee-related Liabilities, Current 2.28M USD -2.15%
Accrued Liabilities, Current 5.43M USD -50.8%
Liabilities, Current 11.8M USD -62.9%
Operating Lease, Liability, Noncurrent 1.63M USD -49.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 13.5M USD -61.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 35K USD
Retained Earnings (Accumulated Deficit) -477M USD -9.21%
Stockholders' Equity Attributable to Parent 142M USD
Liabilities and Equity 156M USD +451%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.97M USD +47.3%
Net Cash Provided by (Used in) Financing Activities 107M USD
Net Cash Provided by (Used in) Investing Activities -98.2M USD -1870%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 12.2M shares +175%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 379K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9M USD +24.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 547K USD -14.7%
Deferred Tax Assets, Valuation Allowance 106M USD +11.3%
Deferred Tax Assets, Gross 106M USD +11.3%
Operating Lease, Liability 3.24M USD -30.7%
Depreciation 600K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.2M USD +9.68%
Lessee, Operating Lease, Liability, to be Paid 3.48M USD -33.4%
Property, Plant and Equipment, Gross 4.46M USD -1.57%
Operating Lease, Liability, Current 1.61M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.69M USD -5.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.8M USD +2.72%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 244K USD -56%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.69M USD -5.96%
Deferred Tax Assets, Operating Loss Carryforwards 63.1M USD +6.72%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.69M USD 0%
Additional Paid in Capital 619M USD +44.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 6.15M USD +77.1%
Interest Expense 652K USD -35.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%